LLY vs RMD: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
LLY is the larger of the two ($1.20T market cap): the incumbent the market prices for continued execution (26.59x forward earnings, beta 0.39). RMD is the smaller challenger ($33.49B), cheaper on forward earnings (18.00x): more room to run, but more to prove. If you believe in growth, LLY fits: analysts expect its revenue to rise 16% next year, against 6% for RMD. If you believe in paying less for profit, RMD fits: it trades at 18x forward earnings, against 26.59x for LLY.
LLY vs RMD: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | LLY | RMD | What it tells you |
|---|---|---|---|
| Market cap | $1.20T | $33.49B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 26.59 | 18.00 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 43.90 | 21.68 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.39 | 0.76 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 80% of range | 59% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 29.93 | 5.63 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: RMD is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how LLY and RMD affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LLY and RMD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LLY and RMD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Eli Lilly (LLY) do?
Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.
What does ResMed (RMD) do?
ResMed sells the equipment and software used to treat sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions outside the hospital. The hardware side splits into flow generators (the AirSense and AirCurve device families, plus the Astral and Stellar life support ventilators) and the masks, cushions, tubing and filters patients replace on a rolling schedule. In fiscal 2026, the year ended June 30, 2026, Americas devices produced ~$1.77 billion and Americas masks and other ~$1.51 billion, while the rest of the world contributed ~$1.12 billion in devices and ~$572 million in masks. A third line, Residential Care Software, brought in ~$676 million from Brightree, MEDIFOX DAN and MatrixCare, the back office systems that home medical equipment dealers, out of hospital care providers and skilled nursing operators use for billing, resupply and scheduling. Roughly 11,370 employees support ~35 million cloud connected devices and ~37 million patients registered in AirView, the remote monitoring platform. Manufacturing is concentrated in Singapore, Sydney and Tijuana. The company is incorporated in Delaware, reports in US dollars, lists on the NYSE, and also trades in Australia as CHESS Depositary Interests.
LLY vs RMD: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
- RMD drivers: Resupply, not new device placements, carries the growth; The Astral recall is a sized, dated hole rather than an open ended one.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: LLY trades at a premium valuation (about 44x trailing and 27x forward earnings, and roughly 14x sales, as of November 20, 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. For RMD, philips is the single largest competitive variable.
LLY or RMD: which should you pick?
If the story you believe is LLY's (GLP-1 obesity and diabetes leadership), LLY is the more direct way to own it; if it is RMD's (Resupply, not new device placements, carries the growth), RMD is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LLY and RMD guides.
LLY vs RMD: the full fundamentals
LLY. At about $1,353 a share on November 20, 2026, Eli Lilly is valued near $1.2 trillion, roughly 44x trailing earnings and 27x the roughly $50.87 in EPS analysts expect for 2027. That premium rests on revenue growth near 39% in the latest quarter and margins (about 51% operating) that few drugmakers have reached. The debate centers on how large and durable the incretin market proves, how oral therapies such as Foundayo change it, and how Novo Nordisk and new entrants shape pricing; the mean analyst target of about $1,470 sits roughly 9% above the price.
RMD. At ~$238 the stock trades near 21.7x trailing GAAP earnings and ~18x forward estimates, below the ~30x it commanded before the GLP-1 debate began. Fiscal 2027 guidance of $5.75 billion to $5.85 billion of revenue and $12.00 to $12.25 of non-GAAP EPS absorbs the ~$75 million Astral headwind and the MatrixCare sale, and the first quarter's $2.91 of non-GAAP EPS puts the year on pace for the upper half of that range if it repeats, while revenue growth of ~5.9% sits inside the 5% to 7% core guide. Mature medtech multiple, double digit EPS growth target: that is the valuation argument in one line.
Headline figures (approximate, November 2026): LLY shows revenue (ttm) ~$86.5 billion, q3 2026 revenue ~$24.4 billion (up ~39% YoY), q3 2026 eps $7.48 vs ~$6.35 est., gross / operating margin (ttm) ~84% / ~51%; RMD shows revenue (trailing twelve months and fiscal 2026) ~$5.73 billion for the twelve months to September 30, 2026. Fiscal 2026, the twelve months ended June 30, 2026, brought ~$5.65 billion, up ~10% reported and ~8% in constant currency from ~$5.15 billion in fiscal 2025, ~$4.69 billion in fiscal 2024 and ~$4.22 billion in fiscal 2023. The September 2026 quarter, the first of fiscal 2027, produced ~$1.41 billion, up ~5.9% year on year and slightly above the ~$1.39 billion consensus, after the Astral sales suspension and the MatrixCare divestiture., earnings and margins Trailing twelve month GAAP net income of ~$1.59 billion and trailing GAAP EPS of ~$10.98, on a ~61.8% gross margin, ~34.0% operating margin and ~27.8% net margin. September 2026 quarter GAAP net income was ~$418 million, up ~23% year on year, and non-GAAP EPS was $2.91 against ~$2.67 expected. For fiscal 2026, GAAP diluted EPS was $10.43 and non-GAAP $11.17, up 17%, with GAAP gross margin of 61.1% and non-GAAP 62.4%; the fourth quarter carried a $42 million Astral provision., revenue mix (the line a screener misses) Fiscal 2026 devices totalled ~$2.89 billion (~$1.77 billion Americas, ~$1.12 billion rest of world), masks and other consumables ~$2.09 billion (~$1.51 billion Americas, ~$572 million rest of world), and Residential Care Software ~$676 million. Sleep and Breathing Health was ~$4.98 billion of the total. Masks grew 10% in the Americas and 12% internationally in the fourth quarter on a constant currency basis, against ~4% constant currency growth for software across the year., cash flow and balance sheet Trailing operating cash flow of ~$1.77 billion and free cash flow of ~$1.30 billion, per Yahoo Finance, against ~$1.81 billion and ~$1.65 billion for fiscal 2026. Cash of ~$1.01 billion against ~$611 million of total debt at September 30, 2026, a net cash position and a debt to equity ratio near 0.10. Cash was ~$1.47 billion at June 30, 2026, when ~$457 million of assets were held for sale for the pending MatrixCare disposal..
The bottom line: LLY vs RMD
LLY and RMD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined LLY and RMD exposure against your real portfolio. It is not an investment adviser.
Wondering how LLY or RMD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Eli Lilly
Ask Walnut's AI anything about LLY and see how it fits what you own.
FAQ
What is the difference between LLY and RMD?
+
Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. ResMed sells the equipment and software used to treat sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions outside the hospital. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is LLY or RMD the better stock?
+
Neither is universally better. LLY is the larger incumbent; RMD is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, LLY or RMD?
+
On forward P/E (as of November 2026), LLY trades at 26.59x and RMD at 18.00x, so RMD is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both LLY and RMD?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of LLY vs RMD?
+
LLY: LLY trades at a premium valuation (about 44x trailing and 27x forward earnings, and roughly 14x sales, as of November 20, 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. Competition is intense, especially from Novo Nordisk, and a wave of next-generation oral and combination incretins from multiple companies could pressure share and pricing. Eventual patent expirations and the prospect of compounded or generic competition are long-term overhangs. Drug pricing politics, insurance and reimbursement coverage decisions, and manufacturing or safety setbacks are material risks. Pipeline candidates can fail in trials, and the heavy concentration of the growth story in metabolic medicines raises single-category dependence. The balance sheet has also become more leveraged as Lilly funds capacity: debt was about $49.5 billion against about $4.9 billion of cash at September 30, 2026, and trailing free cash flow of about $9.3 billion is far below operating cash flow of about $30.7 billion because of heavy capital spending. Revenue growth also slowed from about 48% in the second quarter to about 39% in the third as the base gets larger, and GAAP net income fell quarter over quarter, so the pace of growth is now part of the debate. RMD: Philips is the single largest competitive variable. Its Respironics business exited most of the US new device market after the 2021 foam recall and the subsequent consent decree, handing ResMed several points of share it did not have to compete for. Any credible return of Philips capacity to the US sleep market would meet a ResMed that has been pricing and allocating capital against a diminished rival for five years, and mask share, where switching costs are lowest, would be the first place to show it. The GLP-1 question is genuinely open. ResMed's 2.5 million patient study is observational and self published, and it measures behaviour in the early years of drug adoption rather than the steady state after sustained weight loss; a cohort that loses enough weight to fall below the diagnostic threshold would leave the resupply base entirely. Quality systems are the second live risk. A Class 1 designation on 168,069 Astral units invites FDA scrutiny that can extend past the specific defect into inspection findings, warning letters or a consent decree, and Philips is the cautionary case for how far that can go. Reimbursement adds pressure from the other side: most US revenue passes through home medical equipment suppliers paid by Medicare and commercial plans, so competitive bidding rounds and prior authorisation tightening compress the distributor before they reach ResMed. Manufacturing is concentrated in Singapore, Sydney and Tijuana, which leaves the gross margin exposed to tariffs and freight. Roughly a third of revenue is non-US, so a stronger dollar reduces reported growth. Finally, short interest near 10.9% in August and a 52 week range of $180.27 to $277.67, with the stock ~2.3% lower over a year even as trailing GAAP earnings grew to ~$1.59 billion and quarterly earnings rose ~23% year on year, mean sentiment, not fundamentals, has been setting the price. Revenue growth of ~5.9% in the September quarter, down from 9% in June, is the number the GLP-1 bears will point to until the Astral and MatrixCare effects lap.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell LLY or RMD; figures are approximate and dated (as of November 2026). Verify current data before investing.